@article{cd76ade06d9b4ac69b4ae5e453b4104e,
title = "Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials",
abstract = "Recurrent microsatellite stable (MSS) endometrial cancer has poor response to conventional therapy and limited efficacy with immune checkpoint monotherapy. We conducted a retrospective study of recurrent MSS endometrial cancer patients enrolled in immunotherapy-based clinical trials at MD Anderson Cancer Center between 1 January 2010 and 31 December 2019. Patients were evaluated for radiologic response using RECIST 1.1 criteria, progression-free survival (PFS), and overall survival (OS). Thirty-five patients were treated with immune checkpoint inhibitors: 8 with monotherapy, 17 with immunotherapy (IO) in combination with another IO-only, and 10 with IO in combination with non-IO therapy. Among those treated with combination IO plus non-IO therapy, one had a partial response but 50% had clinical benefit. Patients who received combination IO plus non-IO therapy had improved PFS compared to those who received monotherapy (HR 0.56, 95% CI 0.33–0.97; p = 0.037) or combination IO-only therapy (HR 0.36, 95% CI 0.15–0.90; p = 0.028) and had improved OS when compared to monotherapy after adjusting for prior lines of therapy (HR 0.50, 95% CI 0.27–0.95; p = 0.036). The potential beneficial clinical outcomes of combination IO plus non-IO therapy in MSS endometrial cancer should be validated in a larger study.",
keywords = "clinical trials, endometrial cancer, immune checkpoint inhibitors, immunotherapy, microsatellite stable",
author = "How, {Jeffrey A.} and Jazaeri, {Amir A.} and Siqing Fu and {Rodon Ahnert}, Jordi and Jing Gong and Bettzy Stephen and {Ferreira Dalla Pria}, Hanna and Priya Bhosale and Amber Johnson and Ying Yuan and Funda Meric-Bernstam and Aung Naing",
note = "Funding Information: J.A.H. reports grants from the National Institutes of Health and Cedars Cancer Foundation; A.A.J. reports personal fees from Gerson and Lehrman Group, Guidepoint, Iovance, NuProbe, Simcere, Pact Pharma, Instill Bio, Agenus, and Macrogenics outside submitted the work. He also reports grants from AstraZeneca, Bristol Myers Squibb, Iovance, Aravive, Pfizer, Immatics USA, Eli Lilly, Merck, and stock/stock options from AvengeBio outside the submitted work; S.F. reports research grand funding from the NIH, Abbisko, BeiGene, BioAtla, Boehringer Ingelheim, Eli Lilly&Co., Green2Bio, Hookipa Biotech, IMV, Innovent Biologics, K-Group Beta, Lyvgen Biopharm, MacroGenics, Millennium Pharmaceuticals, Nerviano Medical Sciences, NeuPharma, Novartis, NovoCure, Parexel International, Sellas Life Sciences Group, Soricimed Biopharma, Treadwell Therapeutics, Turnstone Biologics, Taiho Oncology, and NCCN outside the submitted work; J.R.A. reports receiving consulting and travel fees from Novartis, Eli Lilly, Orion Pharmaceuticals, Servier Pharmaceuticals, Peptomyc, Merck Sharp&Dohme, Kelun Pharmaceutical/Klus Pharma, Spectrum Pharmaceuticals Inc, Pfizer, Roche Pharmaceuticals, Ellipses Pharma, NovellusDx, Ionctura, Molecular Partners (including serving on the scientific advisory board from 2015-present), European Society of Medical Oncology, Department of Defense, Louisian State University, Huntsman Cancer Institute, Cancer Core Europe, Karolinska Cancer Institute, King Abdullah International Medical Research Center, WIN Consortium, European Journal of Cancer, VHIO/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, SOLTI, Elsevier, and Jansen outside submitted work. He is also receiving research funding from Bayer, Novartis, Blueprint Pharmaceuticals, Bayer, Tocagen, Spectrum Pharmaceuticals, Symphogen, BioAlta, Pfizer, Takeda-Millennium, GlaxoSmithKline, and Ipsen outside the submitted work. Amber Johnson is part of the Precision Oncology Decision Support (PODS) team at MD Anderson Cancer Center that receives funding from the Royal Phillips Healthcare during the conduct of this study; Y.Y. reports personal fees from AbbVie, Amgen, BeyondSpring Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, Servier Pharmaceuticals, Starpax Pharmaceuticals, and Vertex Pharmaceuticals outside the submitted work; F.M.B. reports research grants from Aileron Therapeutics, Inc, AstraZeneca, Bayer, Calithera Biosciences, Curis, CytomX Therapeutics, Daiichi Sankyo, Debiopharm International, eFFECTOR Therapeutics, Genentech-Roche, Guardant Health, Klus Pharma, Millennium Pharmaceuticals, Novartis, Puma Biotechnology, and Taiho Pharmaceuticals outside the submitted work. She also reports consulting fees from Aduro BioTech, Alkermes, AstraZeneca, DebioPharm, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., Genentech-Roche., IBM Watson, Jackson Laboratory, Kolon Life Science, OrigiMed, PACT Pharma, Parexel International, Pfizer, Samsung Bioepis, Seattle Genetics, Tyra Biosciences, Xencor, and Zymeworks outside the submitted work. She is an advisory committee for Immunomedics, Inflection Biosciences, Mersana Therapeutics, Puma Biotechnology, Seattle Genetics, Silverback Therapeutics, Spectrum Pharmaceuticals, and Zentalis outside the submitted work. She reports honoraria from Chugai Biopharmaceuticals, Mayo Clinic, and Rutgers Cancer Institute of New Jersey, and traveling fees from Beth Israel Deaconess Medical Center outside the submitted work; A.N. reports grants from the National Cancer Institute, EMD Serono, MedImmune, Healios Oncology Nutrition, Atterocor/Millendo, Amplimmune, ARMO BioSciences, Eli Lilly, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, ImmuneOncia, and Surface Oncology outside submitted work. He is an advisory board committee member for CytomX Therapeutics, Novartis, Genome&Co, OncoSec, Kymab, and STCube Pharmaceuticals and receives traveling fees outside submitted work. His spouse receives research funding support from Immune Deficiency Foundation, Ting Tsung and Wei Fong Chao Foundation, and Baxalta outside submitted work. His spouse is also an advisory board member of Takeda, CSL, Behring, Horizon, and Pharming outside the submitted work; J.G., B.S., H.F.D.P., and P.B. have nothing to disclose. Funding Information: This work was supported by the NIH/NCI under award numbers P30CA016672 (supporting the MD Anderson Clinical Trials Office, Biostatistics Resource Group, and Tissue Biospecimen and Pathology Resource) and T32CA101642 (J.A.H.). Furthermore, this study was supported by the uterine SPORE grant (CA098258) and the Dr. Henry R. Shibata Fellowship Award/Cedars Cancer Foundation (J.A.H.). Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
month = aug,
doi = "10.3390/cancers14153695",
language = "English (US)",
volume = "14",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "15",
}